Diagnostic Testing for Serious Veterinary Fungal Infections

Since 2002, MiraVista Diagnostics has been developing and evolving our menu of diagnostic tests for veterinary fungal infections. We work with veterinary clinics, animal hospitals and animal science universities across the country to detect, analyze and monitor a wide range of serious mycology infections that afflict their patients. This includes antifungal therapeutic drug monitoring (TDM) as well as antigen and antibody detection tests for aspergillus, blastomyces dermatitidis, histoplasma capsulatum, coccidioides, cryptococcus and beta-D glucan.

Accurate Test Results Lead to Better Patient Outcomes

MiraVista Diagnostics understands the critical role we play in the veterinary science and health continuum. Because we take that responsibility seriously, we are committed to consistently delivering:

  • Superior clinical standards in testing accuracy and sensitivity
  • Rapid response and test results
  • Dedication to excellent client service and customer satisfaction
  • Direct access to our infectious disease experts
  • Quality assurance across our organization
  • Compliance with regulatory mandates and industry best practices
  • Continuous product and service improvement
Company News

MiraVista Diagnostics Supports Fungal Disease Awareness Week

August 14–18, 2017, is the first Fungal Disease Awareness Week. CDC and partners have organized this week to highlight the importance of recognizing serious fungal diseases early enough in the course of a patient’s illness to provide life-saving treatment. MiraVista…
READ MORE →

MiraVista is Participating in the 2017 Coccidioidomycosis Study Group Symposium

MiraVista Diagnostics is participating in the 2017 Coccidioidomycosis Study Group Symposium on August 11-13 at the Stanford University Medical School. Representatives from the company’s clinical laboratory will be available to discuss MiraVista’s menu of diagnostic tests for serious fungal infections….
READ MORE →

NEW: MVista® Histoplasma Antibody IgG IgM EIA

Improve Diagnosis of Acute Pulmonary Histoplasmosis by Combining Antigen & Antibody Testing Review the technical specifications for the NEW MVista® Histoplasma Antibody IgG IgM EIA>> CLINICAL BACKGROUND Acute pulmonary histoplasmosis (APH) can be severe, especially following heavy exposure and is…
READ MORE →

BULLETIN: CSTE Revised Its Histoplasmosis Position Statement at the 2016 Annual Conference

The Council of State and Territorial Epidemiologists (CSTE) approved the Infectious Disease Committee’s revisions to the histoplasmosis position statement, “Standardized Surveillance Case Definition for Histoplasmosis” at the organization’s annual conference in Anchorage, Alaska on June 19-23, 2016. Review the revised…
READ MORE →

FEATURE: Diagnosing Histoplasmosis by Antigen Detection

FEATURED CASE REPORT FROM THE DESK OF: Lawrence Joseph Wheat, MD Medical Director, Founder & President of MiraVista Diagnostics Here is an important patient case report I’d like to share with colleagues about diagnosing histoplasmosis by antigen detection. I welcome…
READ MORE →

NEW: MVista® Coccidioides Antibody IgG IgM EIA

Improve Coccidioidomycosis Diagnosis with a New, More Sensitive, Anti-Coccidioides Antibody Enzyme Immunoassay CLINICAL BACKGROUND Coccidioidomycosis is endemic to the southwestern United States, northern Mexico and regions of Central and South America. Coccidioidomycosis often presents as community acquired pneumonia (CAP) and…
READ MORE →

LEARN MORE
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo